Physician profile
Ushasree Chamarthy
NPI 1033215967
$1,011.89
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $36.30 · 2021: $92.32 · 2023: $113 · 2024: $65.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $157 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $157.25 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $254.36 | 2019-2020 | |
| Genentech USA, INC. | $122.69 | 2019 | |
| Adc Therapeutics America, INC. | $91.59 | 2023 | |
| Apellis Pharmaceuticals, INC. | $80.40 | 2021 | |
| Abbvie INC. | $65.66 | 2024 | |
| Novartis Pharmaceuticals Corporation | $57.63 | 2019 | |
| Amgen INC. | $56.08 | 2019 | |
| Seagen INC. | $35.30 | 2019 | |
| Merck Sharp & Dohme LLC | $32.11 | 2019 | |
| Kite Pharma, INC. | $29.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $27.11 | 2019 | |
| Pfizer INC. | $26.65 | 2019 | |
| Gilead Sciences, INC. | $23.81 | 2019-2021 | |
| Janssen Biotech, INC. | $23.41 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.81 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Agios Pharmaceuticals, INC. | $17.99 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.33 | 2019 | |
| Lilly USA, LLC | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ushasree Chamarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.